Related Experiment Videos
-Differential antithrombotic therapy in patients with low and high PTCA risk-
1Herzkatheterlabor der Kardiologischen Gemeinschaftspraxis, Klinìk Dr. Müller, München.
Insights
Antithrombotic drugs help prevent acute coronary occlusion and restenosis after interventions. Newer agents like glycoprotein IIb/IIIa inhibitors show promise, but bleeding risks require careful consideration for optimal patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Interventional Cardiology
Background:
- Acute coronary occlusion and restenosis are significant challenges in coronary interventions.
- Thrombus formation is implicated in both acute occlusion and restenosis.
- Effective antithrombotic strategies are crucial for improving outcomes.
Purpose of the Study:
- To review the efficacy of conventional and novel antithrombotic drugs.
- To assess their role in preventing acute occlusion and restenosis, excluding stent-related issues.
- To summarize the current evidence on antithrombotic therapy in interventional cardiology.
Main Methods:
- Review of existing literature on antithrombotic drug use in coronary interventions.
- Analysis of controlled studies and clinical trials evaluating drug efficacy.
- Focus on drugs used for preventing acute occlusion and restenosis.
Main Results:
- Heparin is standard, but prolonged use offers no advantage in low-risk patients. Coumadin does not influence restenosis.
- Aspirin (ASA) plus heparin reduces acute occlusions; newer agents like hirudin and glycoprotein (GP) IIb/IIIa inhibitors show promise.
- GP IIb/IIIa inhibitors significantly reduce ischemic events, but increase bleeding risk. Oral GP IIb/IIIa inhibitors require further study.
Conclusions:
- For high-risk percutaneous transluminal coronary angioplasty (PTCA), consider hirudin over heparin and add GP IIb/IIIa inhibitors.
- ASA is effective against acute occlusions; newer agents warrant further investigation for restenosis prevention.
- Balancing efficacy and bleeding risk is key when selecting antithrombotic therapies.
Abstract:
Acute coronary occlusion as well as restenosis still represent the major limitations of coronary interventions. Either event seems to be related to thrombus formation. The purpose of this overview is to summarize the current status of the usefulness of conventional and newer antithrombotic drugs regarding the prevention of acute occlusion and restenosis (excluding stents).
Anticoagulation:
For ethical reasons, no placebo-controlled studies were conducted to prove the usefulness of heparin in preventing acute occlusions. The dosage mostly used is 10,000 U, although a relationship between dosage and complication rate has not been documented. A prolonged heparin infusion in patients with low risk and uncomplicated PTCA has no advantages. Restenosis is not influenced by prolonged infusion of heparin or administration of coumadin as well. Low molecular weight heparin is currently under investigation. Hirudin and hirulog have shown promising results with less acute occlusions; however, their therapeutic range must be considered. ANTIAGGREGATION: In controlled studies, ASA significantly reduced acute occlusions during PTCA when given in addition to heparin. Ticlopidin is as effective as ASA, but due to its side effects should only be administered when contraindications to ASA exist. ASA significantly reduced restenosis in only 1 of 4 studies with limited number of patients. Thromboxane inhibitors such as ridogrel or clopidogrel showed promising initial results. Trapidil significantly reduced restenosis in 2 studies; quantitative stenosis analysis, however, was not performed. Inhibition of platelets by glycoprotein (GP) IIb/IIIa receptor antagonists represents an innovative therapeutic concept: numerous controlled trials have documented a significant reduction in cardiac ischemic events and therefore indirectly in restenosis rates. The recombinant monoclonal antibody c7E3 Fab seems to be more effective than the synthetic integrelin. Unfortunately, efficacy appears to be in direct relationship to the risk of bleeding complications. The clinical role of oral GP IIb/IIIa inhibitors has yet to be established. For patients with high risk PTCA, the use of hirudin instead of heparin as well as the addition of GP IIb/IIIa inhibitors should be considered.